Thursday, March 22, 2012

POZEN shares up 21 percent, with positive results in trials for aspirin therapy

Shares in Pozen (Nasdaq:POZN) is spiking upward today after the company reported positive results from late-stage clinical trials for a proposed aspirin therapy.
In pre-market trading, shares have already jumped 21 percent to $5.80, up $1.

Pozen's compounded is touted by some as "ulcer safe aspirin."
The Chapel Hill firm reported early Thursday that its PA3250 compound met the primary endpoint of two Phase 3 clinical trials - reducing the incidence of gastric ulcers in patients taking aspirindaily in a dose of at least 325 miligrams.
Based on the results, Pozen said it planned to submit a New Drug Application to the FDA in the third quarter of this year.
Pozen is developing the compound on its own but is searching for a development partner.
“We are encouraged by the strength of the data and I commend the clinical team here at Pozen and all our associates for their dedication and hard work,” said John Plachetka, Pozen's chairman and chief executive officer. “This information is essential to progress our PA32540 partnership discussions for the United States, and to allow us to continue to move forward with our preparations for a third quarter NDA submission for this product candidate.”
Pozen said the compound also met "key secondary endpoints" in the trials.
Changes in Board
In other news, in an SEC filing, Pozen disclosed that two of its board members are stepping down.
James Mauzey and Angela Larson were up for re-election at the company's annual board meeting on June 7.

No comments:

Post a Comment